Literature DB >> 22544607

Construction of an immunostimulatory plasmid, pUCpGs10, and research on its immune adjuvant effect.

Li Tang1, Xiaoyan Feng, Feng He, Rui Huang, Jing He, Bingshui Xiu, Kun Chen, Xiqin Yang, Shigan Ling, Heqiu Zhang.   

Abstract

In order to overcome the instability of CpG ODN in vivo, sequence diversity, and individual differences, eleven CpG ODN fragments were meticulously selected and linked to form a Multi-CpG, which were repeatedly inserted into the cloning vector pUC19 for constructing the recombinant plasmid pUCpGs10 containing ten of Multi-CpG. Using the multi-genotype HCV E1 and multi-epitope complex HCV-T as immunogens, and plasmid pUCpGs10 as the immune adjuvant, Balb/c mice were immunized through nasal and subcutaneous immunization. Strong-specific humoral and cellular immune response were induced, which can obviously inhibit the growth of homograft expressing HCV antigen. The immune adjuvant effect of pUCpGs10 closely matched that of Freund's complete adjuvant. The plasmid pUCpGs10 can significantly improve IgA content in serum and different mucosal extract and systematical T-cell response via intranasal immunization. In conclusions, the newly constructed immunostimulatory plasmid pUCpGs10 is able to effectively activate the humoral and cellular immune activity, and possesses activation on mucosal immune response.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22544607     DOI: 10.1007/s12033-012-9544-5

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.860


  39 in total

Review 1.  Discovery of immunostimulatory CpG-DNA and its application to tuberculosis vaccine development.

Authors:  Saburo Yamamoto; Toshiko Yamamoto; Yasuhiro Nojima; Kiyoko Umemori; Susan Phalen; David N McMurray; Etsuro Kuramoto; Sumiko Iho; Rumiko Takauji; Yukio Sato; Takeshi Yamada; Naoya Ohara; Sohkichi Matsumoto; Yoshitaka Goto; Kazuhiro Matsuo; Tohru Tokunaga
Journal:  Jpn J Infect Dis       Date:  2002-04       Impact factor: 1.362

2.  Intranasal administration of peptide antigens of HIV with mucosal adjuvant CpG ODN coentrapped in microparticles enhances the mucosal and systemic immune responses.

Authors:  Par Bahadur Pun; Ajaz Ahmad Bhat; Teena Mohan; Smita Kulkarni; Ramesh Paranjape; Donthamshetty Nageswara Rao
Journal:  Int Immunopharmacol       Date:  2009-04       Impact factor: 4.932

Review 3.  Autophagy and CD4+ T lymphocyte destruction by HIV-1.

Authors:  Lucile Espert; Mélanie Denizot; Marina Grimaldi; Véronique Robert-Hebmann; Bernard Gay; Mihayl Varbanov; Patrice Codogno; Martine Biard-Piechaczyk
Journal:  Autophagy       Date:  2007-01-14       Impact factor: 16.016

4.  CpG-C ISS-ODN activation of blood-derived B cells from healthy and chronic immunodeficiency virus-infected macaques.

Authors:  N Teleshova; J Kenney; V Williams; G Van Nest; J Marshall; J D Lifson; I Sivin; J Dufour; R Bohm; A Gettie; M Pope
Journal:  J Leukoc Biol       Date:  2006-02       Impact factor: 4.962

5.  Immunostimulatory oligodeoxynucleotide isolated from genome wide screening of Mycobacterium bovis chromosomal DNA.

Authors:  Keun-Wook Lee; Jinwon Jung; Younghee Lee; Tae-Yoon Kim; Soo-Young Choi; Jinseu Park; Doo-Sik Kim; Hyung-Joo Kwon
Journal:  Mol Immunol       Date:  2006-01-26       Impact factor: 4.407

6.  Heterogeneity in the human response to immunostimulatory CpG oligodeoxynucleotides.

Authors:  Cynthia A Leifer; Daniela Verthelyi; Dennis M Klinman
Journal:  J Immunother       Date:  2003 Jul-Aug       Impact factor: 4.456

7.  Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus.

Authors:  John G McHutchison; Bruce R Bacon; Stuart C Gordon; Eric Lawitz; Mitchell Shiffman; Nezam H Afdhal; Ira M Jacobson; Andrew Muir; Mohammed Al-Adhami; Mary L Morris; Julie A Lekstrom-Himes; Susan M Efler; Heather L Davis
Journal:  Hepatology       Date:  2007-11       Impact factor: 17.425

8.  Safety and efficacy of nasal application of CpG oligodeoxynucleotide as a mucosal adjuvant.

Authors:  Satoru Kodama; Nobuyuki Abe; Takashi Hirano; Masashi Suzuki
Journal:  Laryngoscope       Date:  2006-02       Impact factor: 3.325

9.  Impact of immunomodulatory oligodeoxynucleotides on cytokine production in the lipopolysaccharide-stimulated human whole blood model.

Authors:  Robert L Smith; Tae W Chong; Micheal G Hughes; Traci L Hedrick; Heather L Evans; Shannon T McElearney; Alison R Saalwachter; Daniel P Raymond; Kangping Du; Christine K Rudy; Timothy L Pruett; Robert G Sawyer
Journal:  Surgery       Date:  2004-08       Impact factor: 3.982

10.  A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals.

Authors:  Ruth D Ellis; Gregory E D Mullen; Mark Pierce; Laura B Martin; Kazutoyo Miura; Michael P Fay; Carole A Long; Donna Shaffer; Allan Saul; Louis H Miller; Anna P Durbin
Journal:  Vaccine       Date:  2009-05-15       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.